Life
FDA Reconsiders Injectable Peptide Compounding Regulations
The FDA's potential shift on injectable peptide compounding could reshape industry practices, previously hindered by safety concerns. The ongoing conflict in Iran is also affecting trial recruitment.
Editorial Staff
1 min read
The FDA is reportedly reassessing its position on compounding pharmacies, particularly concerning injectable peptides that were previously banned due to safety issues.
This reconsideration could lead to significant changes in how compounding pharmacies operate, potentially increasing the availability of these products.
Additionally, the ongoing war in Iran is impacting recruitment for clinical trials, which may complicate the landscape for new peptide therapies.